



Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Yongyi Zeng
lamp197311@126.com

Lei Wang
wangleiy001@126.com

Jingfeng Liu
drjingfeng@126.com

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 25 May 2022

Accepted: 26 May 2022

Published: 07 June 2022

Citation:

Ke Q, Xin F, Fang H, Zeng Y, Wang L
and Liu J (2022) Corrigendum: The
Significance of Transarterial Chemo
(embolization) Combined With
Tyrosine Kinase Inhibitors and Immune
Check Point Inhibitors for
Unresectable Hepatocellular
Carcinoma in the Era of Systemic
Therapy: A Systematic Review.
Front. Immunol. 13:952446.
doi: 10.3389/fimmu.2022.952446

Qiao Ke^{1,2†}, Fuli Xin^{1,2†}, Huipeng Fang^{2†}, Yongyi Zeng^{1*}, Lei Wang^{2,3*} and Jingfeng Liu^{4,5*}

¹ Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China, ² College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China, ³ Department of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China, ⁴ Department of Hepatopancreatobiliary Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China, ⁵ The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, systematic review

A Corrigendum on:

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

By Ke Q, Xin F, Fang H, Zeng Y, Wang L and Liu J (2022) *Front. Immunol.* 13:913464. doi: 10.3389/fimmu.2022.913464.

In the original article, references 47 and 48 was incorrectly inserted as

47: Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. *HPB (Oxford)* (2019) 21(4):425-33. doi: 10.1016/j.hpb.2018.08.001;

48: Wang L, Ke Q, Deng M, Huang X, Zeng J, Liu H, et al. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy: a real world study. *Scand J Gastroenterol* (2019) 54(11):1403-11. doi: 10.1080/00365521.2019.1684986.

The correct references are as follows:

47: Zhang WW, Hu BY, Han J, Wang HG, Wang ZB, Ye HY, et al. A Real-World Study of PD-1 Inhibitors Combined With TKIs for HCC With Major Vascular Invasion as the Conversion Therapy:

A Prospective, Non-Randomized, Open-Label Cohort Study. *Ann Oncol* (2020) 31:S1307. doi: 10.1016/j.annonc.2020.10.195;

48: Li CJ, Zhou J. Initial Report of a Two-Stage Resection for Hepatocellular Carcinoma Following Downstaging With Transarterial Chemoembolization and Sorafenib. *Fubu Waike* (2017) 30:295-8+301. doi: 10.3969/j.issn.1003-5591.2017.04.015.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ke, Xin, Fang, Zeng, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.